The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decisionmaking. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.
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Learning Objectives:
Upon completion of this activity, participants will be able to:
• 
HEREDITARY BREAST AND/OR OVARIAN CANCER SYNDROME TESTING CRITERIA a,b
• Individual from a family with a known deleterious BRCA1/BRCA2 mutation Meeting one or more of these criteria warrants further personalized risk assessment, genetic counseling, and often genetic testing and management. Testing of unaffected individuals should only be considered when an appropriate affected family member is unavailable for testing.
• High-Risk Assessment: Breast and Ovarian focus primarily on assessment of mutations in the genes BRCA1/2, TP53, and PTEN. The main focus of these NCCN Guidelines is on the management of breast and ovarian cancer risk, and genetic testing and counseling in individuals with these particular genetic mutations. These guidelines were developed with an acute awareness of the preliminary nature of much of the knowledge regarding the clinical application of the rapidly emerging field of molecular genetics, and with an appreciation of the need for flexibility when applying these guidelines to individual families. They are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling, to provide genetic professionals with an updated tool for the assessment of individual breast cancer and ovarian cancer risk and to guide decisions related to genetic testing, and to facilitate a multidisciplinary approach in the management of individuals at increased risk of hereditary breast and/or ovarian cancer.
Genetic Evaluation and Testing
Genetic testing is a complex process involving several phases. First, an initial risk assessment is performed to determine whether genetic assessment should be undertaken. Next, a patient would undergo a formal risk assessment, including a detailed family history, a personal medical and surgical history, a focused physical examination, and an evaluation of the patient's needs and concerns. Testing may be offered; counseling should be performed both before and after testing. and moved to a new set of pages titled "Principles of Cancer Risk Assessment and Counseling" (available online, in the full version of these guidelines, at NCCN.org [BR/OV-A]). Given the complexity of genetic testing and the rapid evolution of molecular diagnostics, the panel agreed that listing the principles on a single set of pages, as opposed to throughout the guidelines as footnotes, would clarify the panel's position on testing principles. For the most recent guidelines update, the panel revised recommendations regarding multigene testing. Minor modifications were also made to testing criteria for genetic mutations, including clarification regarding ovarian cancer histology and revision of BRCA1/2 testing criteria for those with a personal history of pancreatic cancer and with Ashkenazi Jewish ancestry.
Multigene Testing
Next-generation sequencing allows for the sequencing of multiple genes simultaneously. In this approach, referred to as multigene testing, a set of genes that are associated with a specific family cancer phenotype or multiple phenotypes are simultaneously analyzed. The recent introduction of multigene testing for hereditary forms of cancer has rapidly altered the clinical approach to testing at-risk patients and their families. This approach may detect mutations not found in single-gene testing. Multigene testing could include only high-penetrance genes associated with a specific cancer, or both high-and moderatepenetrance genes. Comprehensive cancer risk panels, which include a large number of genes associated with a variety of cancer types, are also available. NCCN Guidelines Insights 
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implications of moderate-penetrance genes included in a panel). The panel also included recommendations for both the provider and laboratories. During the panel meeting for the 2015 update, several members noted that this section should be more concise, because some of the most important points were difficult to identify in the presented text. The panel's recommendations regarding multigene testing now more clearly emphasize the following (GENE-1, this page):
• Multigene testing should ideally be offered in the context of professional genetic expertise.
• Multigene testing may be more efficient and/or cost-effective for patients who have a family history suggestive of an inherited cancer syndrome and in the setting of clinical features common to more than one hereditary syndrome or more than one gene.
• Multigene testing may also be warranted in those who have tested negative (indeterminate) for a single inherited syndrome but whose personal or family history remains strongly suggestive of an inherited susceptibility.
• Both the laboratory and test panel should be chosen carefully and limitations understood. The panel also noted that multigene testing may include moderate-penetrance genes. Currently, there are limited data and no specific guidelines regarding degree of cancer risk associated with some moderate-penetrance genes and management for gene carriers. [4] [5] [6] These issues are compounded by the low incidence rates of hereditary disease, making it difficult to conduct adequately powered studies. 4 The approach to risk management after detection of a mutation in a moderate-risk gene and how best to communicate risk to relatives are currently unknown. 7 Ideally, testing should only be performed for genes that are clinically actionable. The panel now provides recommendations regarding risk manage-NCCN Guidelines Insights ment for less common moderate-penetrance genes (see later discussion). Finally, the panel noted that multigene tests increase the likelihood of detecting a variant of unknown significance (VUS). 3, [5] [6] [7] [8] [9] The considerable possibility of detecting a VUS adds to the complexity of counseling for multigene testing.
ADDIT-2 BREAST AND OVARIAN MANAGEMENT BASED ON GENETIC TEST RESULTS
Ovarian Cancer Histology and Genetic Mutations
During the meeting for the 2015 guidelines update, the panel debated whether the criteria for genetic risk evaluation should be more specific regarding ovarian cancer histology. The histology of ovarian cancers in carriers of a BRCA1/2 mutation is more likely to be characterized as serous adenocarcinoma and high grade compared with ovarian cancers in nonmutation carriers. However, endometrioid and clear cell ovarian cancers have also been reported in BRCA1/2 carriers. [10] [11] [12] [13] [14] [15] Mutations are also associated with nonmucinous ovarian carcinoma as opposed to mucinous. 16, 17 Mucinous epithelial ovarian carcinomas may be associated with other gene mutations, such as KRAS and TP53 mutations. 18 Nonepithelial ovarian carcinomas (eg, germ cell and sex cord stromal tumors) are not significantly associated with BRCA1/2 mutations, 19 but they may be associated with other cancer genetic syndromes, such as PeutzJeghers syndrome. [20] [21] [22] [23] Current data indicate that ovarian low-malignant-potential tumors (ie, borderline epithelial ovarian tumors) are also not associated with BRCA1/2 mutations. 16 Based on these study findings, the following modifications were made to the genetic risk evaluation guidelines (BR/OV-1, page 155):
• "Epithelial ovarian cancer" was replaced with "invasive ovarian cancer." • The footnote was modified to indicate that BRCA-related ovarian cancers are associated with epithelial nonmucinous histology, although NCCN Guidelines Insights CE other cancer genetic syndromes may be associated with ovarian cancer that is mucinous or nonepithelial.
Pancreatic Cancer Risk and BRCA1/2 Mutations BRCA1/2 mutations are associated with an increased propensity for developing pancreatic cancer. [24] [25] [26] [27] [28] In an analysis of samples from patients with familial pancreatic cancer (kindreds in which ≥3 family members had pancreatic cancer, at least 2 of whom were first-degree relatives), BRCA2 mutations were detected in 17% of patient samples. 27 Patients with pancreatic cancer who also have Ashkenazi Jewish ancestry may have a greater likelihood of testing positive for a BRCA1/2 mutation, with prevalence of detected mutations in this group ranging from 5.5% to 19%, and with mutations in BRCA2 (4%-11%) being more common than BRCA1 (1%-8%). [29] [30] [31] In 211 Ashkenazi Jewish patients with breast cancer who had a family history of pancreatic cancer, 6.6% had a BRCA1 mutation and 7.6% had a BRCA2 mutation. 32 Regarding testing criteria for BRCA1/2 mutations, the panel previously recommended that criteria for those with a personal history of pancreatic cancer would be the same as for those with a personal history of prostate cancer; specifically, a personal history of pancreatic or prostate cancer, with at least 1 close relative with breast cancer diagnosed at age 50 years or younger and/or invasive ovarian cancer and/or pancreatic or prostate cancer diagnosed at any age. Given the elevated risk for pancreatic cancer in BRCA1/2 carriers 24, 25, 27, 28, 33 relative to the risk for prostate cancer, 28, 33 and the short survival of most patients with pancreatic cancer (which limits the ability to perform genetic testing in these individuals in the future), the panel argued that less stringent criteria are warranted for testing in those with a personal history of pancreatic cancer. Based on concerns raised by 2 panel members, the panel now recommends that a family history of prostate cancer is no longer a criterion for testing in those with a personal history of pancreatic cancer. Furthermore, a personal history of pancreatic cancer combined with Ashkenazi Jewish ancestry warrants testing, given the considerable rates of BRCA1/2 mutations in Ashkenazi Jewish patients with pancreatic cancer (HBOC-1, page 156 ).
29-31
Risk Management Recommendations
The panel's recommendations regarding screening and risk reduction for those found to have a genetic mutation associated with hereditary cancer are based on existing evidence. Changes made for the 2015 update include refinement of risk management recommendations for less common genetic mutations associated with breast and/or ovarian cancer, and recommendations regarding ovarian cancer riskreducing surgery in BRCA1/2 mutation carriers.
Less Common Genetic Mutations Associated With Breast/Ovarian Cancer
In these NCCN Guidelines, the panel focuses specifically on assessment of known high-penetrance mutations (ie, BRCA1/2, TP53, PTEN). In the 2014 update, the panel added CDH1, STK11/LKB1, and Lynch syndrome to the guidelines as other genes associated with increased breast and/or ovarian cancer risk. Although evidence is limited, other genes have been shown to be associated with increased cancer risk, including ATM, CHEK2, PALB2, BARD1, BRIP1, RAD51C, and RAD51D.
During the 2015 guidelines update meeting, the panel debated the possibility of including information and recommendations for these less common genes, including population frequency, estimated cancer risks, and management strategies. The panel ultimately decided that providing this amount of detailed information in the guidelines for all of the rare genes noted would be premature, given the current state of the evidence. Risk management recommendations should be evidence-based and matched to cancer risk and should only be made for genes that are clinically actionable. Because risk may differ between breast and ovarian cancers, different recommendations may need to be made for these 2 cancer types.
Based on this logic, the panel created a new table summarizing which gene mutations are associated with breast and/or ovarian cancer risk, and when breast MRI, risk-reducing mastectomy (RRM), and risk-reducing salpingo-oophorectomy (RRSO) should be recommended or considered (ADDIT-2, page 159). Breast MRI is recommended when the gene mutation is associated with at least a 20% lifetime risk of breast cancer. This threshold was identified in breast cancer risk models dependent on family history (see NCCN Guidelines for Breast NCCN Guidelines Insights CE Cancer Screening and Diagnosis and for Breast Cancer Risk Reduction for more information; available at NCCN.org). 34, 35 Most of the recommendations in this new table are extrapolated from BRCA studies, because no strong evidence exists regarding risk management recommendations for the other genes. Genes for which there is little to no existing evidence suggesting an association with breast and/or ovarian cancer risk are noted in a row titled "Insufficient evidence for intervention." Intervention may be warranted based on family history or other clinical factors. The recommendations in this table can be used to inform which genes may be included in multigene testing (see earlier discussion).
Salpingectomy in BRCA1/2 Mutation Carriers
Salpingectomy (surgical removal of the fallopian tube) has recently gained attention as a potential procedure to reduce the risk of ovarian cancer. Salpingectomy rates are increasing, especially in women younger than 50 years. 36 Its use is supported by the finding that high-grade serous carcinomas may originate in the fallopian tube. [37] [38] [39] This procedure allows patients to avoid the disadvantages of oophorectomy, such as lack of ovarian preservation and onset of early menopause. 40 Salpingectomy has been shown to be a safe and feasible procedure when performed at the same time as hysterectomy. 36, 41 Despite evidence regarding the safety and feasibility of salpingectomy, more data are needed regarding its efficacy in reducing the risk of ovarian cancer. 37, 42 Furthermore, BRCA1/2 carriers who undergo salpingectomy without oophorectomy may not get the 50% reduction in breast cancer risk associated with oophorectomy. During the 2015 update meeting, a panel member presented data showing that, although ovarian carcinomas often originate in the fallopian tube, a significant minority (>20%) originates in the ovary. [43] [44] [45] [46] For these reasons, the panel included a statement that salpingectomy is not the standard of care, and risk-reducing salpingectomy alone or outside the context of a clinical trial is not recommended (HBOC-A, page 157).
Summary and Conclusions
In summary, the panel discussed several pertinent issues this year, including multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also made the following changes to the 2015 recommendations:
• Consolidated recommendations regarding testing and counseling principles into a new set of pages, titled "Principles of Cancer Risk Assessment and Counseling," • Added more specific language regarding ovarian cancer histology criteria for genetic risk evaluation, and • Revised testing criteria for BRCA1/2 mutations for those with a personal history of pancreatic cancer and who have Ashkenazi Jewish ancestry. The evidence base for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes is rapidly evolving. It is essential for recommendations to reflect the current state of the evidence.
